literature

HIV mutation literature information.

Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.

PMID: 34897227 2022 Journal of acquired immune deficiency syndromes (1999)

Table: L74V/I

Table: L74V

Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes.

PMID: 34873084 2022 AIDS (London, England)

Table: L74V

Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria.

PMID: 34741609 2022 The Journal of antimicrobial chemotherapy

Result: There was only one participant who had more than one class of minority variant in the absence of any resistance mutations at >=20% frequency, and they had a core NRTI minority variant L74V at 8.6% and NNRTI minority variant E138A at 2.4%.

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.

PMID: 34694878 2022 Antimicrobial agents and chemotherapy

Table: L74V

HIV-1 Drug Resistance and Genetic Transmission Networks Among MSM Failing Antiretroviral Therapy in South China 2014-2019.

PMID: 34377002 2021 Infection and drug resistance

Table: L74I/V

Determination of reverse transcriptase inhibitor resistance mutations in HIV-1 infected children in Cote d'Ivoire.

PMID: 33170745 2021 Genome

Abstract: Frequently encountered resistance mutations were for NRTIs: M184V (88%), TAMs (67%), T215F/I/V/Y (33%), and L74I/V (24%); for NNRTIs: K103N/S (74%), P225H (26%), and G190A/E/Q (24%).

Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.

PMID: 33892628 2021 BMC infectious diseases

Result: Eleven NOPs (I72V, L74MVI, L101I, T112V, T124A, T124A, G134N, I135V, K136K/Q, V201I and T206S) are part of the CCD, and the remaining five (T218I, L234I, A265V, R269K and S283G) belong to the CTD.

Result: The consensus sequences generated using the database-derived HIV-1 CRF02_AG sequences (n = 287) and cohort sequences (n = 20), identified 20 naturally occurring polymorphisms (NOPS):

PMID: 34573296 2021 Genes

Result: The most prevalent RT RAMs among children and adolescents and their relative proportions were as follows: M184V (76.6%, n = 49/64), K103N (45.3%, n = 29/64), Y181C/V/I (28.1%, n = 18/64), T215F/Y (25.0%, n = 16/64), V108I (18.8%, n = 12/64), A98G (15.6%, n = 10/64), G190A (12.5%, n = 8), K101E/H (12.5%, n = 8), M41L (10.9%, n = 7/64), L74I/V (10.9%, n = 7/64), and H221Y (10.9%, n = 7/64) (Figure 1a,b).

Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study.

PMID: 34622871 2021 Medicine

Result: M184 V/I 87 (28.8%), K65R/E/N 27 (8.9%), L74 V 3 (1.0%), and Y115F 12 (4.0%) were the mutations conferring resistance to NRTIs, along with thymidine analog mutations (TAMs) M41L 14 (4.6%), D67N 17 (5.6%), K70R 20 (6.6%), L210W 10 (3.3%), T215Y/F 23 (7.6%), K219Q/E 32 (10.6%), and K65R/E/N 27 (8.9%).

Correlation of HIV-1 drug resistant mutations and virologic failure.

PMID: 34584606 2021 The Pan African medical journal

Abstract: Out of 17 new mutations, 14 resulted in virologic failure and included NRTIs (L74I, L74V, T69D, V65R);

Result: Most of the new mutations also encoded for resistance to prescribed drugs and these included L74I/V, T69D, V65R as NRTIs; A98G, V179E/F/D/F as NNRTs and I54V, F53L, L89T, G48A, K20T as PIs.

Table: L74V

Browser Board

Co-occurred Entities

Filtrator